Hussman Strategic Advisors Inc. Has $1.38 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Hussman Strategic Advisors Inc. lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 63.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,500 shares of the company's stock after selling 17,900 shares during the quarter. Hussman Strategic Advisors Inc.'s holdings in Neurocrine Biosciences were worth $1,383,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sunbelt Securities Inc. raised its position in Neurocrine Biosciences by 34.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 325 shares of the company's stock worth $37,000 after buying an additional 83 shares during the last quarter. Lindbrook Capital LLC increased its stake in Neurocrine Biosciences by 85.0% in the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company's stock valued at $28,000 after purchasing an additional 96 shares in the last quarter. Red Spruce Capital LLC raised its holdings in Neurocrine Biosciences by 0.6% during the fourth quarter. Red Spruce Capital LLC now owns 16,026 shares of the company's stock worth $2,112,000 after purchasing an additional 101 shares during the last quarter. Metis Global Partners LLC boosted its position in Neurocrine Biosciences by 4.7% during the third quarter. Metis Global Partners LLC now owns 2,361 shares of the company's stock worth $266,000 after purchasing an additional 106 shares in the last quarter. Finally, Signaturefd LLC grew its holdings in Neurocrine Biosciences by 5.2% in the fourth quarter. Signaturefd LLC now owns 2,511 shares of the company's stock valued at $331,000 after purchasing an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock traded up $1.66 on Monday, hitting $133.66. The stock had a trading volume of 575,066 shares, compared to its average volume of 840,158. The stock's 50 day moving average is $136.21 and its 200-day moving average is $127.35. The firm has a market capitalization of $13.30 billion, a price-to-earnings ratio of 55.23 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company's revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 earnings per share. Equities analysts expect that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on NBIX shares. Cantor Fitzgerald reissued an "overweight" rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Wells Fargo & Company upped their target price on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the company an "equal weight" rating in a report on Thursday, February 8th. Wedbush reiterated an "outperform" rating and set a $147.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, April 17th. Mizuho upped their price objective on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, February 8th. Finally, Barclays lifted their target price on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 23rd. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $139.67.

Insider Activity at Neurocrine Biosciences

In other news, Director Richard F. Pops sold 15,000 shares of the business's stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total value of $1,987,050.00. Following the completion of the sale, the director now owns 29,512 shares of the company's stock, valued at approximately $3,909,454.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Kevin Charles Gorman sold 2,707 shares of the business's stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total transaction of $380,847.83. Following the sale, the chief executive officer now directly owns 502,188 shares of the company's stock, valued at $70,652,829.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard F. Pops sold 15,000 shares of the firm's stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the completion of the transaction, the director now owns 29,512 shares of the company's stock, valued at $3,909,454.64. The disclosure for this sale can be found here. Insiders have sold 186,994 shares of company stock valued at $25,806,409 over the last ninety days. Corporate insiders own 4.60% of the company's stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.